Thursday 26th September 2019

19:15 - 20:15



I.  Biologic Insights:  E- Poster Walkers: Marion Wobser & Elina Theodorakopoulou


  • Number 034 - The diagnostic and prognostic value of five blood markers in cutaneous T-cell lymphomas: a validation cohort
  • Number 035 - Upregulation of integrin-associated protein on tumor T cells in CTCL inhibits IL-12 and Th1 immunity
  • Number 039 - Genetic alterations in CD30-positive lymphoproliferations
  • Number 043 - Sequential comprehensive molecular work-up of treatment resistant mycosis fungoides with systemic dissemination during a 4-year period
  • Number 037 - Cutaneous T cell lymphoma mouse model used to study the therapeutic mechanisms of phototherapy



II.  Histopathology: E- Poster Walkers:  Maxime Battistella & Maritina Roppa


  • Number 063 - Diagnostic and clinical significance of eccrinotropism in mycosis fungoides
  • Number 064 - Large cells with CD30 expression and Hodkin-like features in primary cutaneous marginal zone B-cell lymphoma: a study of 13 cases
  • Number 066 - Primary cutaneous peripheral T cell lymphoma not otherwise specified: a comparative clinicopathological analysis of 5 cases
  • Number 067 - Pediatric lymphomatoid papulosis
  • Number 068 - Infection with human T-cell lymphotropic virus type-1 in primary cutaneous lymphoma: Should we be testing all patients
  • Number 069 - Challenges in the diagnosis of CD30+ anaplastic large-cell lymphoma



III.  Treatment: E-poster Walkers: Iris Amitay-Laish &  Eirini Kapniari


  • Number 102 - Selective inhibition of HDAC6 sensitizes CTCL to PI3K inhibitors
  • Number 098 - Contemporary treatment patterns and response in relapse/refractory cutaneous T-cell lymphoma (CTCL) in clinical practice in, France, Germany Italy, Spain and the United Kingdom
  • Number 099 - Systemic rituximab in the treatment of indolent primary cutaneous B-cell lymphomas
  • Number 100 - Treatment of Sézary syndrome with alemtuzumab: a case series (2009-2019)
  • Number 038 - Clonality assessment in blood and immunotyping of malignant cells to support choice of treatment for erythrodermic CTCL patients, a CD52 success story of precision medicine



IV.  Biologics/Psoriasis and CTCL & Quality of Life: E-poster Walkers: Florentia Dimitriou 

& Kyriaki Lampadaki


  • Number 117 -  Mycosis fungoides progression in the setting of ustekinumab therapy for psoriasis: Report of two cases
  • Number 123 - Lymphoproliferative diseases among patients treated with biologicals. A case study and single center survey.
  • Number 046 - Pityriasis lichenoides in patients with mycosis fungoides – our experience
  • Number 118 - A case of mycosis fungoides with large cell transformation following dupilumab treatment
  • Number 109 - Effect of oral psoralen plus UV-A (PUVA) photochemotherapy on quality of life, anxiety and depression in patients with early-stage mycosis fungoides
  • Number 111 - Quality of life in Greek patients with mycosis fungoides – a cross- sectional study


Important Dates

Registrations open:
November 1st 2018

Abstract submission begins:
January 1st 2019

Deadline for Early Registration:
June 30st 2019

Abstract submission deadline extended:
June 17th 2019


Scientific Programme

Follow us on

Organized by

Scientific / Secretarial Support

Free Spirit

12 Thessalonikis str., 15344 Gerakas, Athens - Greece
+30 210 60 48 260


Financial Management / Logistics


9 Vassili Michaelides, 3026 Limassol - Cyprus
+357 95 150 291

© EORTC CLTF 2019 "Insights in research and patient care" - 26-28 September 2019, Athens Greece